AxoGen, Inc. (AXGN) vs Mineralys Therapeutics, Inc. (MLYS)
A side-by-side comparison of AxoGen, Inc. and Mineralys Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AXGN
AxoGen, Inc.
$36.52HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
MLYS
Mineralys Therapeutics, Inc.
$22.39HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — AXGN vs MLYS
growth of $100 · dividends reinvested · last 4yAXGN +300.6% (+41.5%/yr)MLYS +26.4% (+6.0%/yr)AXGN compounded faster over this window
AXGN MLYS
AXGN vs MLYS: by the numbers
- •MLYS is the larger company ($1.97B vs $1.96B market cap).
- •Both run net losses; MLYS's is the smaller (0.00% vs -13.36% net margin).
Metrics side by side
Valuation
| Metric | AXGN | MLYS |
|---|---|---|
| Forward P/E | 82.53 | N/A |
| P/S ratio | 7.82 | N/A |
| P/B ratio | 7.66 | 3.58 |
| FCF yield | 0.13% | N/A |
Profitability
| Metric | AXGN | MLYS |
|---|---|---|
| Gross margin | 74.56% | 0.00% |
| Operating margin | -5.12% | 0.00% |
| Net margin | -13.36% | 0.00% |
| ROE | -13.09% | -63.45% |
| ROIC | -4.68% | -57.17% |
Growth (annualized)
| Metric | AXGN | MLYS |
|---|---|---|
| Revenue CAGR (5Y) | 13.99% | N/A |
| Total return CAGR (5Y) | 19.40% | N/A |
Go deeper
Dig into the metrics
AxoGen ROEMineralys Therapeutics ROEAxoGen operating marginMineralys Therapeutics operating marginAxoGen revenue growthMineralys Therapeutics revenue growthAxoGen free cash flowMineralys Therapeutics free cash flow
AxoGen & Mineralys Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.